OP-352

**OP-352** is an investigational small-molecule drug candidate originally developed by Arena Pharmaceuticals and later advanced by Outpost Medicine for pelvic floor and gastrointestinal disorders, particularly stress urinary incontinence and fecal incontinence. Publicly available information indicates that it reached early clinical testing, including a 2019 single- and multiple-ascending-dose study in healthy younger and elderly participants designed to assess safety, tolerability, pharmacokinetics, and food effect. The precise molecular target and mechanism of action have not been clearly disclosed in reliable public primary sources; secondary pipeline databases broadly characterize it as a GPCR modulator, but without enough specificity to assign a confident target-level mechanism.